How Shum was paid
$430,863 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Other | Total |
|---|---|---|---|---|---|
| Steven ShumChief Executive Officer | $278,757 | $75,000 | $52,106 | $25,000 | $430,863 |
| Terah KrigsvoldChief Financial Officer | $250,000 | $50,000 | $36,474 | — | $336,474 |
| Andrea GorenChief Business Officer; Former Chief Financial Officer | $218,761 | $20,000 | $43,769 | — | $282,530 |
| Dr. Daniel TeperFormer President | $260,000 | — | — | — | $260,000 |
What changed and why
- $431K$430,863 was the CEO’s 2025 total compensation, versus $260,000 in 2024.
- $75,000$75,000 was the CEO’s 2025 performance bonus for successfully uplisting to Nasdaq.
- $52,106$52,106 was the grant-date value of the CEO’s 1,250-share stock option award.
- $336K$336,474 was CFO Terah Krigsvold’s 2025 total compensation, including a $50,000 bonus.
- $250K$250,000 was Andrea Goren’s amended base salary after changing from CFO to chief business officer.
- $260K$260,000 of Dr. Daniel Teper’s 2025 salary was deferred and assumed by NAYA Therapeutics.
Other INVO Fertility proxy statements
- 2025 proxy statement
Steven Shum paid $260,000 (+12% on the year).
Filed Dec 18, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.